Alpha 2.0
Login Register
» Authors » Martin Hendrix

Martin Hendrix

Explore the profile of Martin Hendrix including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 10
Citations 515
Followers 0
Related Specialties
Pharmacology
Neurology
Molecular Biology
Top 10 Co-Authors
Christina Erb
Marja van Kampen
Arjan Blokland
Frank G Boess
Jos Prickaerts
F Josef van der Staay
Adrian Tersteegen
Jean De Vry
Timo Flessner
Carsten Schmeck
Published In
Neuropharmacology
Nat Med
Mol Pharmacol
Eur J Pharmacol
Antimicrob Agents Chemother
Affiliations
Soon will be listed here.
Recent Articles
1.
Pharmacological and behavioral profile of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-chinolincarboxamide (EVP-5141), a novel α7 nicotinic acetylcholine receptor agonist/serotonin 5-HT3 receptor antagonist
Boess F, De Vry J, Erb C, Flessner T, Hendrix M, Luithle J, et al.
Psychopharmacology (Berl) . 2012 Dec; 227(1):1-17. PMID: 23241647
Rationale And Objective: Agonists of α7 nicotinic acetylcholine receptors (nAChRs) may have therapeutic potential for the treatment of cognitive deficits. This study describes the in vitro pharmacology of the novel...
2.
The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents
van der Staay F, Rutten K, Barfacker L, Devry J, Erb C, Heckroth H, et al.
Neuropharmacology . 2008 Aug; 55(5):908-18. PMID: 18674549
The present study investigated the putative pro-cognitive effects of the novel selective PDE9 inhibitor BAY 73-6691. The effects on basal synaptic transmission and long-term potentiation (LTP) were investigated in rat...
3.
The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents
Boess F, De Vry J, Erb C, Flessner T, Hendrix M, Luithle J, et al.
J Pharmacol Exp Ther . 2007 Feb; 321(2):716-25. PMID: 17308038
The relative contribution of alpha4beta2, alpha7 and other nicotinic acetylcholine receptor (nAChR) subtypes to the memory enhancing versus the addictive effects of nicotine is the subject of ongoing debate. In...
4.
Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors
Rutten K, Prickaerts J, Hendrix M, van der Staay F, Sik A, Blokland A
Eur J Pharmacol . 2007 Jan; 558(1-3):107-12. PMID: 17207788
The present study investigated the time-dependent memory enhancing properties of three selective phosphodiesterase inhibitors (PDE-I) vardenafil (PDE5-I), rolipram (PDE4-I) and BAY 60-7550 (PDE2-I) in the object recognition task. In particular,...
5.
In silico ADMET traffic lights as a tool for the prioritization of HTS hits
Lobell M, Hendrix M, Hinzen B, Keldenich J, Meier H, Schmeck C, et al.
ChemMedChem . 2006 Sep; 1(11):1229-36. PMID: 16991174
The need for in silico characterization of HTS hit structures as part of a data-driven hit-selection process is demonstrated. A solution is described in the form of an in silico...
6.
Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits
Wunberg T, Hendrix M, Hillisch A, Lobell M, Meier H, Schmeck C, et al.
Drug Discov Today . 2006 Mar; 11(3-4):175-80. PMID: 16533716
Drug-like and lead-like hits derived from HTS campaigns provide good starting points for lead optimization. However, too strong emphasis on potency as hit-selection parameter might hamper the success of such...
7.
Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line
Wunder F, Tersteegen A, Rebmann A, Erb C, Fahrig T, Hendrix M
Mol Pharmacol . 2005 Sep; 68(6):1775-81. PMID: 16150925
We report here the in vitro characterization of 1-(2-chlorophenyl)-6-[(2R)-3,3,3-trifluoro-2-methylpropyl]-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidine-4-one (BAY 73-6691), the first potent and selective inhibitor of phosphodiesterase 9 (PDE9), which is currently under preclinical development for the treatment...
8.
Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance
Boess F, Hendrix M, van der Staay F, Erb C, Schreiber R, van Staveren W, et al.
Neuropharmacology . 2004 Nov; 47(7):1081-92. PMID: 15555642
An essential element of the signalling cascade leading to synaptic plasticity is the intracellular second messenger molecule guanosine 3',5'-cyclic monophosphate (cGMP). Using the novel, potent, and selective inhibitor Bay 60-7550,...
9.
Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293
Betz U, Fischer R, Kleymann G, Hendrix M, Rubsamen-Waigmann H
Antimicrob Agents Chemother . 2002 May; 46(6):1766-72. PMID: 12019088
BAY 57-1293 belongs to a new class of antiviral compounds and inhibits replication of herpes simplex virus (HSV) type 1 and type 2 in the nanomolar range in vitro by...
10.
New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease
Kleymann G, Fischer R, Betz U, Hendrix M, Bender W, Schneider U, et al.
Nat Med . 2002 Apr; 8(4):392-8. PMID: 11927946
The vast majority of the world population is infected with at least one member of the human herpesvirus family. Herpes simplex virus (HSV) infections are the cause of cold sores...